What distinguished Epicutis skincare from the market since its 2021 launch—namely its bio-science heritage, medical-grade yet luxe-feel formulas, lean SKU count, and clinician-centric distribution—continues to fuel the Boulder, Colorado-based brand, alongside a fresh insider cash infusion of $10 million.Now in 3,500 points of distribution worldwide and 30+ countries, the current plan, according to Epicutis founder and CEO Maxwell Stock, is disciplined expansion on all fronts. That means rolling out to fewer than 10 additional international markets within the next five years and adding to the product lineup at a measured pace. By holding the reins tight, Stock hopes to maintain the brand’s steady upward trajectory. From launch-year revenue of approximately $350,000 to 2024 revenue of roughly $13 million, Epicutis has shown a propensity for breaking through the hype and noise of an increasingly cluttered market. Unlike the biggest medspa brands, which serve up a dizzying array of SKUs across multiple product franchises, Epicutis offers just 10 core products. This includes its hero Lipid Serum, a powerful anti-inflammatory crafted from just eight ingredients, along with Oil Cleanser; Hyvia Crème; Arctigenin Brightening Treatment; Lipid Body Treatment; Lipid Recovery Masks for face, neck and décolleté, and eyes; new Hydrobiome Mist; and a selection of bundled sets. Relatively pricey (per the website, individual products start at $85 and top off at $250, and sets range from $75 to $395), Epicutis is clearly positioned at the top of the market.